Phenominer Database Results (44 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Experiment Notes Record ID Study ID
RHA/N defecation rate control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 defecation behavior trait both 111 days-118 days 19 0.74 /5 min 0.07 0.3 ex vivo visual assessment 300.0 0 video monitoring 66024 114
BN/OlaHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 7 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84473 1178
BN/OlaHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 7 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84523 1178
WF/NHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 5 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84525 1178
F344/NHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 3 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84526 1178
SD heart left ventricle infarction area to total heart left ventricle area ratio left anterior descending coronary artery occlusion (for 28 days) Lax CJ, et al., Clin Exp Pharmacol Physiol. 2004 Aug;31(8):512-7. heart left ventricle integrity trait male 77 days 6 35.4 % 1.9 4.65 ex vivo visual assessment 0.0 lad occlusion 28 days 101127 2564
WAG/RijCrl metastatic lung tumor number S4MH cells (250 X 10E3) (for 21 days) then sham surgical control condition (for 11 days) Garc?a-Alonso I, et al., J Surg Res. 2008 Aug;148(2):185-90. doi: 10.1016/j.jss.2007.06.026. Epub 2007 Aug 2. lung integrity trait male 87 days 10 28.5 null 7.68 24.29 ex vivo visual assessment 0.0 S4MH injection 21 days 108162 3119
ACI/SegHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84474 1178
N:HS defecation rate control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 defecation behavior trait both 111 days-118 days 20 2.87 /5 min 3.65 16.34 ex vivo visual assessment 300 0 video monitoring 66023 114
RLA/N defecation rate control condition Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 defecation behavior trait both 111 days-118 days 18 0.22 /5 min 0.02 0.1 ex vivo visual assessment 300 0 video monitoring 66025 114
SHR/NIcoCrlf defecation rate control condition Ramos A, et al., Behav Brain Res. 1998 Nov;96(1-2):195-205 defecation behavior trait female 56 days-63 days 12 0.1 /5 min 0.1 0.35 ex vivo visual assessment 300 0 video monitoring defecation rate measurement 65140 108
LEW.1N percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 6 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84521 1178
ACI/SegHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84524 1178
COP percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 8 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84528 1178
COP percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 8 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84514 1178
LEW.1AV1/Kini percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 41 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84522 1178
F344/NHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84476 1178
DA/ZtmKini percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 5 80.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84529 1178
PVG percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 8 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84531 1178
LEW.1AR1/Ztm percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84533 1178
LEW.1AV1/Kini percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 6 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84536 1178
ACI/SegHsd percentage of study population developing pituitary tumors during a period of time 17 beta-estradiol (27.5 mg) (between 146 and 202 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 pituitary gland integrity trait female 207 days-265 days 21 100.0 % ex vivo visual assessment 0 0 65551 76
WF.DA-(D19Mit1-D19Mit6)/Kop post-insult time to onset of moribundity controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. life span trait both 42 days-222 days 23 179.65 d 0.35 1.67 ex vivo visual assessment 0.0 0 180 day maximum 70328 1339
PVG.1AV1 percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 8 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84516 1178
LEW.1F percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84520 1178
LEW/Han percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 18 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84527 1178
LEW.1WR1/WorBrm percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84532 1178
LEW.1F percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 50.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84534 1178
LEW.1N percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 12 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84535 1178
SD heart left ventricle infarction area to total heart left ventricle area ratio left anterior descending coronary artery occlusion (for 140 days) Lax CJ, et al., Clin Exp Pharmacol Physiol. 2004 Aug;31(8):512-7. heart left ventricle integrity trait male 189 days 10 37.9 % 2.0 6.32 ex vivo visual assessment 0.0 lad occlusion 140 days 101128 2564
LEW/NIcoCrlf defecation rate control condition Ramos A, et al., Behav Brain Res. 1998 Nov;96(1-2):195-205 defecation behavior trait male 56 days-63 days 5 0.6 /5 min 0.6 1.34 ex vivo visual assessment 300 0 video monitoring defecation rate measurement 65137 108
SHR/NIcoCrlf defecation rate control condition Ramos A, et al., Behav Brain Res. 1998 Nov;96(1-2):195-205 defecation behavior trait male 56 days-63 days 12 0.1 /5 min 0.1 0.35 ex vivo visual assessment 300 0 video monitoring defecation rate measurement 65138 108
DA/ZtmKini percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 8 50.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84515 1178
LEW.1WR1/WorBrm percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 37 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84518 1178
PVG.1AV1 percentage of study population developing experimental autoimmune neuritis during a period of time peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 4 25.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84530 1178
LEW/Han percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 29 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84513 1178
WF/NHsd percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 5 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84475 1178
WAG/RijCrl metastatic lung tumor number S4MH cells (250 X 10E3) (for 21 days) then partial hepatectomy (for 11 days) Garc?a-Alonso I, et al., J Surg Res. 2008 Aug;148(2):185-90. doi: 10.1016/j.jss.2007.06.026. Epub 2007 Aug 2. lung integrity trait male 87 days 10 99.2 null 0.54 1.71 ex vivo visual assessment 0.0 S4MH injection 21 days 108163 3119
ACI/SegHsd percentage of study population developing pituitary tumors during a period of time bilateral ovariectomy then 17 beta-estradiol (27.5 mg) (for 140 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 pituitary gland integrity trait female 201 days-203 days 11 100.0 % ex vivo visual assessment 0 0 65561 76
WF/Kga post-insult time to onset of moribundity controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. life span trait both 42 days-222 days 20 180.0 d 0.0 0.0 ex vivo visual assessment 0.0 0 180 day maximum 70327 1339
DA/Slc post-insult time to onset of moribundity controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) Hirano M, et al., Cancer Lett 2005 May 2;. life span trait both 42 days-222 days 20 161.45 d 2.85 12.73 ex vivo visual assessment 0.0 0 180 day maximum 70329 1339
PVG percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 8 0.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84517 1178
LEW.1AR1/Ztm percentage of study population developing experimental autoimmune neuritis during a period of time peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84. peripheral nervous system integrity trait male 98 days-200 days 30 100.0 % ex vivo visual assessment 0.0 0 peripheral nervous system integrity trait 84519 1178
LEW/NIcoCrlf defecation rate control condition Ramos A, et al., Behav Brain Res. 1998 Nov;96(1-2):195-205 defecation behavior trait female 56 days-63 days 6 0.0 /5 min 0.0 0.0 ex vivo visual assessment 300 0 video monitoring defecation rate measurement 65139 108